Investigator meeting · Dr. Liam Dubois

04 Jun 2026 · In person · Dr. Liam Dubois, Peter MacCallum Cancer Centre · MSL Luis Ortega · Lumeva

ReviewedVeeva CRMENG-0202MI request

Capture insight from this engagement

Location: Peter MacCallum Cancer Centre
Therapeutic area: Neurology
Country: Australia
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: LOLuis OrtegaMSL, Neurology (Iberia)
Product: Lumeva (lumevarin)

Topics discussed

Switching between CGRP agents
Medication-overuse headache

Scientific content used

Chronic migraine scientific platform
LMV persistence data summary

Questions raised

What is the persistence rate at 18 months in real-world cohorts?

Notes

Investigator meeting with primary care physician at Peter MacCallum Cancer Centre. Discussed switching between cgrp agents, medication-overuse headache.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Invite to advisory board

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 3
Strategic relevance: 5
Depth of exchange: 3
Actionability: 4

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0202

Audit history (0)

All create, update and approval events for this record

No audit events in sample data